Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy.

Hypertension and pregnancy-related hypertension are major public health problems of largely unknown causes. We describe a mutation in the mineralocorticoid receptor (MR), S810L, that causes early-onset hypertension that is markedly exacerbated in pregnancy. This mutation results in constitutive MR activity and alters receptor specificity, with progesterone and other steroids lacking 21-hydroxyl groups, normally MR antagonists, becoming potent agonists. Structural and biochemical studies indicate that the mutation results in the gain of a van der Waals interaction between helix 5 and helix 3 that substitutes for interaction of the steroid 21-hydroxyl group with helix 3 in the wild-type receptor. This helix 5-helix 3 interaction is highly conserved among diverse nuclear hormone receptors, suggesting its general role in receptor activation.

[1]  H. Gronemeyer,et al.  The nuclear receptor ligand-binding domain: structure and function. , 1998, Current opinion in cell biology.

[2]  P. Chambon,et al.  Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. , 2000, Molecular cell.

[3]  P. Sigler,et al.  Atomic structure of progesterone complexed with its receptor , 1998, Nature.

[4]  F. Holsboer,et al.  Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. , 1993, Molecular endocrinology.

[5]  J. Dunn,et al.  Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. , 1981, The Journal of clinical endocrinology and metabolism.

[6]  D. Housman,et al.  Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. , 1987, Science.

[7]  J. Ott,et al.  Strategies for multilocus linkage analysis in humans. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[8]  H. Hauptman,et al.  The crystal structure and molecular conformation of aldosterone. , 1972, Journal of the American Chemical Society.

[9]  D. Moras,et al.  Antagonism in the human mineralocorticoid receptor , 1998, The EMBO journal.

[10]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[11]  R. Lifton Molecular Genetics of Human Blood Pressure Variation , 1996, Science.

[12]  F. Holsboer,et al.  Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. , 1993, European journal of pharmacology.

[13]  Søren Schifter,et al.  Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I , 1998, Nature Genetics.